JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD. Financials JiangSu WuZhong Pharmaceutical Development Co., Ltd.
Equities
600200
CNE000000YP4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.68 CNY | -1.73% |
|
-6.02% | +17.76% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,791 | 6,038 | 5,390 | 5,791 | 6,819 | - | - |
| Enterprise Value (EV) 1 | 3,791 | 6,038 | 5,390 | 5,791 | 6,819 | 6,819 | 6,819 |
| P/E ratio | -7.57 x | 286 x | -71.5 x | -81.4 x | 50.4 x | 31.4 x | 18.8 x |
| Yield | - | - | - | - | 0.52% | 0.83% | - |
| Capitalization / Revenue | - | - | 2.66 x | 2.59 x | 2.42 x | 2.1 x | 1.74 x |
| EV / Revenue | - | - | 2.66 x | 2.59 x | 2.42 x | 2.1 x | 1.74 x |
| EV / EBITDA | - | - | 165 x | -226 x | 27.1 x | 17.7 x | 12.4 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 3.02 x | 3.36 x | 3.7 x | 3.29 x | 2.95 x |
| Nbr of stocks (in thousands) | 704,560 | 704,560 | 704,560 | 704,457 | 704,457 | - | - |
| Reference price 2 | 5.380 | 8.570 | 7.650 | 8.220 | 9.680 | 9.680 | 9.680 |
| Announcement Date | 4/28/21 | 4/26/22 | 4/26/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2,026 | 2,240 | 2,815 | 3,246 | 3,930 |
| EBITDA 1 | - | - | 32.69 | -25.62 | 251.3 | 385 | 550 |
| EBIT 1 | - | - | -75.14 | -72.16 | 140.3 | 266.4 | 406.5 |
| Operating Margin | - | - | -3.71% | -3.22% | 4.98% | 8.21% | 10.34% |
| Earnings before Tax (EBT) 1 | - | - | -75.4 | -71.19 | 140.3 | 266 | 407.5 |
| Net income 1 | -506.4 | 22.72 | -76.2 | -71.95 | 137.3 | 220.8 | 368 |
| Net margin | - | - | -3.76% | -3.21% | 4.88% | 6.8% | 9.37% |
| EPS 2 | -0.7110 | 0.0300 | -0.1070 | -0.1010 | 0.1920 | 0.3080 | 0.5150 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | 0.0500 | 0.0800 | - |
| Announcement Date | 4/28/21 | 4/26/22 | 4/26/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -4.25% | -4.06% | 7.31% | 10.7% | 15.8% |
| ROA (Net income/ Total Assets) | - | - | -1.99% | - | 3% | 4.88% | 6.6% |
| Assets 1 | - | - | 3,834 | - | 4,577 | 4,525 | 5,576 |
| Book Value Per Share 2 | - | - | 2.530 | 2.450 | 2.610 | 2.940 | 3.280 |
| Cash Flow per Share 2 | - | - | 0.0800 | -0.2900 | 0.1700 | 0.4400 | 0.5000 |
| Capex 1 | - | - | 40.8 | 82.4 | 43.5 | 106 | - |
| Capex / Sales | - | - | 2.01% | 3.68% | 1.55% | 3.26% | - |
| Announcement Date | 4/28/21 | 4/26/22 | 4/26/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.68
CNY
Average target price
12.7
CNY
Spread / Average Target
+31.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.76% | 941M | |
| +42.69% | 749B | |
| +38.42% | 605B | |
| -6.87% | 351B | |
| +18.74% | 328B | |
| +6.76% | 292B | |
| +18.77% | 248B | |
| -2.33% | 214B | |
| +11.23% | 216B | |
| +2.64% | 167B |
- Stock Market
- Equities
- 600200 Stock
- Financials JiangSu WuZhong Pharmaceutical Development Co., Ltd.
